CA Patent

CA3025854A1 — Methods for treating heterotopic ossification

Assigned to Clementia Pharmaceuticals Inc · Expires 2017-12-14 · 8y expired

What this patent protects

The invention features dosing regimens and pharmaceutical formulations for oral administration of palovarotene. The dosing regimens can reduce heterotopic ossification, reduce the number of flare- ups, and/or reduce the severity of flare-ups in subjects suffering from fibrodyspla…

USPTO Abstract

The invention features dosing regimens and pharmaceutical formulations for oral administration of palovarotene. The dosing regimens can reduce heterotopic ossification, reduce the number of flare- ups, and/or reduce the severity of flare-ups in subjects suffering from fibrodysplasia ossificans progressiva.

Drugs covered by this patent

Patent Metadata

Patent number
CA3025854A1
Jurisdiction
CA
Classification
—
Expires
2017-12-14
Drug substance claim
No
Drug product claim
No
Assignee
Clementia Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.